Please assess the completion status of the following clinical trial:

Trial Title: Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent form~* Age 18-75 years~* Able to adhere to the study visit schedule and other protocol requirements~* Patients with multiple myeloma who have received high-dose therapy and autologous stem cell transplantation as first-line therapy within the last 90 - 120 days and have not shown progressive disease afterwards.~* Patients may have received up to 6 cycles of prior induction therapy and up to 2 cycles of prior mobilisation chemotherapy. A bortezomib or thalidomide induction therapy is allowed. Patients may also have received prior radiation therapy~* Measurable levels of myeloma paraprotein in serum (\>0.5 g/dL) or urine (\>0.2 g/24hours) or measurable free light chains (FLC) in serum (\>50 mg/l) with an abnormal FLC ratio must be documented at the time of first diagnosis.~* ECOG performance status = 2 at study entry~* Laboratory and functional test results within these ranges:~  * ANC ≥ 1,000/μL~ * Platelet count ≥ 100,000/μL~ * Total bilirubin 2.5 mg/dL~ * AST (SGOT) and ALT (SGPT) 3 x ULN~ * Patients with impaired renal function can be included~* The patient must be able to adhere to the pregnancy precautions~* Disease free of prior malignancies for 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast~Exclusion Criteria:~* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form~* Pregnant or breast feeding females~* Any condition or laboratory abnormality which places the subject at an unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study~* Known allergic/hypersensitivity reaction to thalidomide, lenalidomide or any components of the treatment~* Any cutaneous grade ≥ 3 adverse reaction (for example desquamating rash) while taking thalidomide or similar drugs~* Any prior use of lenalidomide~* Known positive for HIV or active infectious hepatitis, type A, B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 25 mg lenalidomide
- 2 (Type: EXPERIMENTAL): 5 mg lenalidomide

Based on this trial design, predict the completion outcome and termination type (if applicable).